Skip to content
Menu
Press Releases
Filter Releases
 
EMERYVILLE, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the first quarter ended March 31, 2017. "In the first quarter, we continued preparing for the potential approval and commercialization of ADS-5102, which, if approved, will be the first ...
EMERYVILLE, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the quarter ended September 30, 2016.  "This was a milestone quarter for the company as we prepared for and submitted our New Drug Application (NDA) for ADS-5102 (amantadine hydrochloride) extended-release ca...
EMERYVILLE, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the second quarter of 2016.  "We are pleased with the progress made during the quarter, especially in our ADS-5102 program.  We announced compelling clinical data in both the Phase 3 program in levodopa-induc...
EMERYVILLE, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the first quarter of 2016.  Adamas ended the quarter with $169.2 million of cash, cash equivalents, and available-for-sale securities compared to $120.0 million at December...
May 10, 2016 Financial Releases HTML PDF
EMERYVILLE, Calif., Feb. 23, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced financial results for the fourth quarter and full year ended December 31, 2015.  Adamas reported a net loss attributable to common stockholders of $51.8 million, or $2.86 per share, for the year ended December 31...
Feb 23, 2016 Financial Releases HTML PDF
EMERYVILLE, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported financial results for the third quarter of 2015.  The company reported a net loss attributable to common stockholders of $14.9 million, or $0.81 per share, for the quarter ended September 30, 2015.  In the sa...
Nov 12, 2015 Financial Releases HTML PDF
EMERYVILLE, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported financial results for the second quarter of 2015. The company reported a net loss attributable to common stockholders of $14.1 million, or $0.78 per share, for the quarter ended June 30, 2015. In the same period last year, the company rep...
Aug 11, 2015 Financial Releases HTML PDF
EMERYVILLE, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported financial results for the first quarter of 2015. "In 2015, we have made continued progress throughout our business, including receiving orphan drug designation for our lead product candidate, ADS-5102, for the treatment of levodopa...
May 13, 2015 Financial Releases HTML PDF
EMERYVILLE, Calif., March 3, 2015 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported financial results for the year ended December 31, 2014. "We made significant progress in 2014, advancing ADS-5102, our lead wholly-owned product candidate, into pivotal Phase 3 clinical trials for the treatment of levodopa-induced dy...
EMERYVILLE, Calif., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported a net loss attributable to common stockholders of $9.6 million, or $0.57 per share, for the quarter ended September 30, 2014. In the same period last year, the company reported a net loss attributable to common stockholders of $3.4 million...
EMERYVILLE, Calif., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported net income attributable to common stockholders of $16.4 million, or $0.88 per share on a fully diluted basis, for the quarter ended June 30, 2014. In the same period last year, the company reported a net loss attributable to common stockho...
EMERYVILLE, Calif., May 13, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported financial results for the quarter ended March 31, 2014. "During the first quarter we continued to develop our lead wholly-owned product candidate, ADS-5102, for the treatment of levodopa-induced dyskinesia in patients with Parkinson's ...
May 13, 2014 Financial Releases HTML PDF
Emeryville, Calif., April 9, 2014 – Adamas Pharmaceuticals, Inc. (Adamas), a specialty pharmaceutical company, today announced the pricing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. The shares are expected to begin tradin...
EMERYVILLE, CALIF., August 18, 2009 - Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has closed a $40 million Series D round of funding led by aeris CAPITAL AG and DAG Ventures. Earlier investors MDV-Mohr Davidow Ventures and Northgate Capital also participated in the round. In conjunction with the financing, t...
Aug 18, 2009 Financial Releases HTML PDF